![]() |
Name |
5'-Epialtenuene
|
Molecular Formula | C15H16O6 | |
IUPAC Name* |
(2R,3S,4aS)-2,3,7-trihydroxy-9-methoxy-4a-methyl-3,4-dihydro-2H-benzo[c]chromen-6-one
|
|
SMILES |
C[C@]12C[C@@H]([C@@H](C=C1C3=C(C(=CC(=C3)OC)O)C(=O)O2)O)O
|
|
InChI |
InChI=1S/C15H16O6/c1-15-6-12(18)10(16)5-9(15)8-3-7(20-2)4-11(17)13(8)14(19)21-15/h3-5,10,12,16-18H,6H2,1-2H3/t10-,12+,15+/m1/s1
|
|
InChIKey |
MMHTXEATDNFMMY-GMXABZIVSA-N
|
|
Synonyms |
5'-Epialtenuene; CHEMBL482028; (2R,3S,4aS)-2,3,7-trihydroxy-9-methoxy-4a-methyl-3,4-dihydro-2H-benzo[c]chromen-6-one
|
|
CAS | NA | |
PubChem CID | 44575247 | |
ChEMBL ID | CHEMBL482028 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 292.28 | ALogp: | 0.7 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 96.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 21 | QED Weighted: | 0.674 |
Caco-2 Permeability: | -4.736 | MDCK Permeability: | 0.00000677 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.099 |
Human Intestinal Absorption (HIA): | 0.057 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.039 |
Blood-Brain-Barrier Penetration (BBB): | 0.462 | Plasma Protein Binding (PPB): | 68.57% |
Volume Distribution (VD): | 0.304 | Fu: | 42.93% |
CYP1A2-inhibitor: | 0.026 | CYP1A2-substrate: | 0.801 |
CYP2C19-inhibitor: | 0.036 | CYP2C19-substrate: | 0.846 |
CYP2C9-inhibitor: | 0.041 | CYP2C9-substrate: | 0.446 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.283 |
CYP3A4-inhibitor: | 0.102 | CYP3A4-substrate: | 0.37 |
Clearance (CL): | 6.767 | Half-life (T1/2): | 0.73 |
hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.16 |
Drug-inuced Liver Injury (DILI): | 0.228 | AMES Toxicity: | 0.251 |
Rat Oral Acute Toxicity: | 0.321 | Maximum Recommended Daily Dose: | 0.866 |
Skin Sensitization: | 0.466 | Carcinogencity: | 0.046 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.119 |
Respiratory Toxicity: | 0.893 |